The Evidence for Pharmacologic Treatment of Neuropathic Cancer Pain: Beneficial and Adverse Effects

摘要: Abstract Context The prevalence of neuropathic pain in patients with cancer has been estimated to be around 40%. Neuropathic may caused by tumor invasion and is considered as mixed nociceptive-neuropathic pain, or an anticancer treatment purely pain. use adjuvant analgesics usually extrapolated from their efficacy nononcological syndromes. Objectives In this systematic review, we sought evaluate the evidence for beneficial adverse effects pharmacologic Methods A review literature PubMed Embase was performed. Primary outcome measures were absolute risk benefit (ARB), defined number a degree relief divided total group, harm (ARH), fraction who dropped out result effects. Results We identified 30 articles that fulfilled our inclusion criteria. Overall, ARB antidepressants, anticonvulsants, other analgesics, opioids greatly outweighed ARH. There no significant differences ARH between four groups medication vs. Because low methodological quality studies, could not draw conclusions about true effect size medications. Conclusion Once diagnosis established cancer, should addition instead opioids.